KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBITDA Margin (2016 - 2025)

Gilead Sciences (GILD) has disclosed EBITDA Margin for 17 consecutive years, with 25.03% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 736.0% year-over-year to 25.03%, compared with a TTM value of 34.04% through Dec 2025, up 2826.0%, and an annual FY2025 reading of 34.04%, up 2826.0% over the prior year.
  • EBITDA Margin was 25.03% for Q4 2025 at Gilead Sciences, down from 42.82% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 51.77% in Q3 2021 and bottomed at 64.64% in Q1 2024.
  • Average EBITDA Margin over 5 years is 25.9%, with a median of 32.4% recorded in 2024.
  • The sharpest move saw EBITDA Margin crashed -9148bps in 2024, then skyrocketed 9820bps in 2025.
  • Year by year, EBITDA Margin stood at 12.98% in 2021, then surged by 136bps to 30.68% in 2022, then dropped by -26bps to 22.66% in 2023, then skyrocketed by 43bps to 32.4% in 2024, then fell by -23bps to 25.03% in 2025.
  • Business Quant data shows EBITDA Margin for GILD at 25.03% in Q4 2025, 42.82% in Q3 2025, and 34.93% in Q2 2025.